Citations

Clear

1056 citation(s) found for "Sharma, P".

Reply to: Beyond Parametric Assumptions: Unsupervised Methods Enhance DNA Repair Gene Discovery in SMARCAL1 Identification
Oak, Ninad , Chen, Wenan , Mori, Motomi , Wu, Gang , Nichols, Kim E. , Sharma, Richa , Wu, Gang , Nichols, Kim E , Sharma, Richa

Mayo Clinic

Journal of Clinical Oncology | March 12, 2026 | Volume: 44 | Issue: 14 | Pages: 1374-1375

10.1200/jco-26-00249 | PMID 41818648 Get It

Long-term follow-up of S0221, comparing alternative dose-schedules of anthracycline and taxane therapy in early breast cancer
Barlow, William E. , Moore, Halle C F, Hobday, T., Isaacs, Claudine, Salim, Muhammad , Albain, Kathy S. , Chew, Helen K. , Burton, G., Srkalović, Gordan , Flaherty, Lawrence E. , Lew, Danika L., Hortobagyi, Gabriel N, Sharma, Priyanka, Pusztai, Lajos, Budd, George T, Moore, Halle C. F. , Isaacs, Claudine , Ali, Azka , Barlow, William E , Moore, Halle C F , Isaacs, Claudine , Albain, Kathy , Srkalovic, Gordan , McGregor, Bradley , Gralow, Julie R , Sharma, Priyanka , Pusztai, Lajos , Budd, G Thomas , Hobday, Timothy J. , McGregor, Bradley A. , Gralow, Julie R. , Hortobágyi, Gabriel N. , Sharma, Priyanka , Pusztai, Lajos , Budd, G. Thomas

Mayo Clinic

JNCI Cancer Spectrum | March 12, 2026 | Volume: 10 | Issue: 2 | Pages: No page available

10.1093/jncics/pkag024 | PMID 41832961 Get It

Abstract Background S0221 investigated weekly vs every 2 weeks dosing of doxorubicin (A) and cyclophosphamide (C) followed by paclitaxel in patients with high-risk early breast cancer. After an interim analysis, random assignment to the 2 AC arms was stopped for futility, and the trial was modified to study only the paclitaxel schedules. Methods Between December 2003 and November 2010, a total of 2716 patients were randomly assigned in a 2 × 2 factorial design to 15 weeks of weekly A and daily C vs 6 cycles of every 2 weeks AC; and weekly paclitaxel for 12 weeks vs 6 cycles of every 2 weeks paclitaxel. Between January 2011 and January 2012, an additional 578 patients were assigned to 4 cycles of every 2 weeks AC and randomly assigned to weekly vs every 2 weeks paclitaxel. Updated survival was assessed using log-rank tests and Cox regression models. We compared outcomes by breast cancer subtype as well. Results At a median follow-up of 12.1 years, there were no statistically significant differences among the 4 treatment arms in disease-free survival (DFS) (P = .91) or overall survival (P = .34) in the original protocol. Among the 578 patients assigned AC for 4 cycles and randomly assigned to paclitaxel weekly vs every 2 weeks paclitaxel, there were no overall differences in DFS (P = .32) or overall survival (P = .42). Conclusion As there were no statistically significant outcome differences in DFS or overall survival between the studied schedules of AC and paclitaxel with extended follow-up in the original or revised protocol, either paclitaxel schedule may be recommended, with selection based on toxicity, cost, or patient preference.
Gatherings in Esophagology: Innovations and Future Directions in the Diagnosis and Management of Reflux Disease
Cable, Jennifer, Giuli, R, Fox, Mark , Rosen, Rachel L., Valdovinos‐García, Luis R., Siboni, Stefano, Clarke, John O. , Samuels, Tina L. , Scarpignato, Carmelo , Fass, Ronnie, Remes-Troche, José María, Khan, Abraham, Rahman, Afrin Kamal, Lynch, Kristle L. , Jodorkovsky, Daniela , Vela, Marcelo F. , Vandenberg, Alexandra, Kuo, Braden, Ergün, Pelin , Jirapinyo, Pichamol, Asti, Emanuele, Tolone, Salvatore, Salvador, Renato , Sozzi, Marco, Husain, Inna, Wu, J. , Hobson, Anthony, Sharma, Nirmal , Gyawali, C. Prakash, Sifrim, Daniel, Savarino, E V, Bortoli, Nicola De, Rogers, Benjamin D. , Clarke, J , Valdovinos-García, Luis R. , Siboni, Stefano , Johnston, Nikki , Stein, Ellen M. , Fass, Ronnie , Remes Troche, José M , Kuo, Braden , Jirapinyo, Pichamol , Asti, Emanuele , Sheu, Eric Garland , Sozzi, Marco , Hobson, Anthony, Lo, Wai–Kit , Duncan, Daniel R. , Gyawali, C. Prakash , Chan, Walter W. , Sifrim, Daniel

Mayo Clinic

Annals of the New York Academy of Sciences | March 12, 2026 | Volume: 1557 | Issue: 1 | Pages: No page available

10.1111/nyas.70225 | PMID 41817458 Get It

ABSTRACT Recent advances in the diagnosis and management of reflux disease were the central focus of the inaugural Gatherings in Esophagology (GiE), which convened experts across gastroenterology, surgery, otolaryngology, pulmonology, and basic research. The sessions highlighted innovations in reflux monitoring—including high‐resolution manometry, wireless pH monitoring, and novel salivary biomarkers—while critically evaluating their diagnostic accuracy and clinical utility. Presentations explored the limitations of traditional proton‐pump inhibitor therapy, the emergence of potassium‐competitive acid blockers as a new class of acid suppressants, and the evolving role of adjunctive treatments such as mucosal protectants, reflux reducers, and neuromodulators for refractory symptoms. The discourse extended to advanced interventional procedures, including transoral incisionless fundoplication, magnetic sphincter augmentation, and the RefluxStop device, with discussion of patient selection, efficacy, and complication management. Discussants emphasized the pathophysiology and management of extraesophageal manifestations of reflux, the interplay between reflux and pulmonary disease, and the diagnostic challenges in pediatric populations. The meeting also addressed the integration of behavioral therapies, the role of the microbiome, and the application of artificial intelligence in reflux diagnostics. Collectively, these insights underscore a shift toward precision medicine in reflux disease, emphasizing individualized diagnostic strategies and tailored therapeutic approaches to improve patient outcomes.
A randomized phase II trial of gemcitabine, nab‐paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer
Jameson, Gayle , Roe, Denise J. , Hanna, Diana L. , Pelster, Meredith S. , Frank, Richard C. , Alistar, Angela , Miller, Alan M. , Wiedmeier‐Nutor, J. Erin, Algaze, Sandra D., Zoller, Alison R., Hallberg, Sarah J. , Wertheim, Betsy C., Lee, Keehoon, Cridebring, Derek , Rabinowitz, Joshua D., Gately, Stephen, Keppler, Jennifer, Sharma, Sunil , Hoff, Daniel D. Von, Rasco, Drew , Wiedmeier, Julia E. , Jameson, Gayle S , Hanna, Diana L , Wiedmeier-Nutor, Julia E , Zoller, Alison R , Lee, Keehoon , Cridebring, Derek , Borazanci, Erkut , Roberts, Caroline G. P. , Algaze, Sandra , Rabinowitz, Joshua D. , Hoff, Daniel D. Von

Mayo Clinic

Cancer | March 12, 2026 | Volume: 132 | Issue: 6 | Pages: No page available

10.1002/cncr.70343 | PMID 41817106 Get It

ABSTRACT Background A randomized phase II screening trial of gemcitabine, nab‐paclitaxel, and cisplatin with a medically supervised ketogenic diet (MSKD) versus usual diet (non‐MSKD) was conducted in patients with treatment‐naive metastatic pancreatic ductal adenocarcinoma (PDAC). Methods Patients with untreated metastatic PDAC were randomized 1:1 to MSKD or non‐MSKD while receiving gemcitabine, nab‐paclitaxel, and cisplatin on days 1 and 8 of a 21‐day cycle. The MSKD was guided by a remote health care team and daily ketone (beta‐hydroxybutyrate) levels, with goal beta‐hydroxybutyrate of 0.5 to 3.0 mM. The primary endpoint was progression‐free survival (PFS) using a one‐sided alpha level of 0.20. Secondary endpoints included overall survival (OS), safety, and quality of life (QOL). Changes in microbiome were an exploratory endpoint. Findings Overall, there were 32 evaluable patients. In the MSKD arm, 15 of 16 patients achieved nutritional ketosis; the median proportion of days in ketosis was 39.4%. The median PFS was 8.5 months in MSKD patients and 6.2 months in non‐MSKD patients: hazard ratio, 0.53 (95% CI, 0.21–1.37); one‐sided p = .096. The median OS was 13.7 months with MSKD and 10.2 months in the non‐MSKD arm: hazard ratio, 0.58 (95% CI, 0.25–1.37); one‐sided p = .107). All MSKD‐related adverse events were grade 1‐2. There were no significant differences in grade ≥3 chemotherapy‐related adverse events between the arms. MSKD patients had no decline in QOL and had significant enrichment of beneficial taxa in the microbiome ( p < .05, log‐fold change ≥2). Conclusions The MSKD is feasible in patients with PDAC and, although not powered for definitive outcomes, shows trends in improved PFS and OS when combined with gemcitabine, nab‐paclitaxel, and cisplatin, without added toxicity or detriment to QOL. Larger studies are required to confirm these findings and establish the value of the MSKD in pancreatic cancer treatment.
Zoledronic acid-induced orbital inflammation: a diagnostic challenge
Nasrini, Tala , Bacon, Adam, Sharma, Umesh, Umesh, Sharma, Sharma, Umesh

Mayo Clinic

European Journal of Case Reports in Internal Medicine | March 5, 2026 | Volume: 13 | Issue: 4 | Pages: No page available

10.12890/2026_005784 | PMID 41988543 Get It

Introduction: Zoledronic acid is a bisphosphonate widely used for osteoporosis and other bone disorders. In rare cases, it can cause ocular inflammation mimicking orbital cellulitis. Case description: A 52-year-old woman developed right eye pain and swelling within 24 hours of her first zoledronic acid infusion. Examination revealed conjunctival redness and mild eyelid swelling without proptosis, ophthalmoplegia, or vision loss. Laboratory markers were largely normal. Computed tomography scan and magnetic resonance imaging showed preseptal and postseptal inflammation without abscess formation. Treatment with corticosteroids and antibiotics resulted in complete symptom resolution within one week. Conclusion: Zoledronic acid can induce rapid-onset orbital inflammation. Awareness of this rare adverse effect is essential to avoid misdiagnosis and ensure timely treatment.
Suppression of early pro-inflammatory senescent signature post-radiotherapy mitigates chronic bone damage
Orme, Jacob J. , Sharma, Ritika, Komel, Aqsa, Khan, Khubaib Gul, White, Thomas A. , LeBrasseur, Nathan K. , Khosla, Sundeep, Pignolo, Robert J. , Chandra, Abhishek, Khosla, Sundeep , Orme, Jacob J , LeBrasseur, Nathan K , Khosla, Sundeep , Pignolo, Robert J , Chandra, Abhishek , Achudhan, David , White, Thomas A, Park, Sean S. , Chandra, Abhishek

Mayo Clinic

No container title available | March 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.01.708630 | PMID 41867754 Get It

Abstract Cellular senescence has been implicated in the pathophysiology of radiotherapy-related bone loss. Based on our previous work, clearance of senescent cells using genetic and pharmacological tools alleviates the anomalies associated with radiation-associated bone deterioration. The pro-inflammatory senescence associated secretome referred to as senescence associated secretory phenotype (SASP), is a hallmark of cellular senescence. The modulation of SASP by senomorphic drugs, potentially can suppress the pro-inflammatory secretome of senescent cells, irrespective of the underlying senescence mechanism. In this study we tested a senomorphic drug, ruxolitinib, a Janus kinase inhibitor (JAKi), during acute and chronic radiotherapy related effects on the bone. Our clinical data indicate an early increase in several pro-inflammatory SASP proteins following radiotherapy of spinal metastasis in prostate cancer patients. Longitudinal assessment of SASP-related genes confirmed this acute elevation in several SASP markers in systemic circulation following irradiation of mouse femurs. In a proof-of-concept study, following two preclinical radiotherapy regimens of cumulative doses of 30Gy (5 x 6Gy) and 60Gy (5 x 12Gy), a senomorphic approach of JAKi treatment was more effective in alleviating radiation-related bone loss compared to the senolytic cocktail of D+Q. Early and intermittent suppression of SASP using JAK inhibitors alleviated chronic bone deterioration, diminished telomere dysfunction, lowered senescence and SASP marker expression, reduced bone-marrow adiposity, and mitigated radiation related lymphatic impairment. Overall, our study shows that early targeting of SASP proteins could be a potential therapeutic to prevent radiotherapy-related chronic bone loss and risk of fractures. Lay Summary Radiotherapy as part of cancer treatment is correlated with an acute increase in senescent cells. Here we show that the pro-inflammatory senescence associated secretory phenotype (SASP) becomes much more prominent soon after radiotherapy in both patients and mice. Suppression of the SASP using a Janus kinase inhibitor, ruxolitinib, reduced the overall senescent cell burden, improved bone architecture by promoting bone formation, reduced bone marrow adiposity, and mitigated radiation-induced lymphatic impairment. Overall, these findings suggest that early inhibition of the SASP may help mitigate several bone anomalies and prevent long-term bone loss and fractures after radiotherapy. Graphical Abstract
Skeletal-related event impact on prostate cancer mortality in the older population in the US: A 24-year trend regression analysis.
Bagga, Arindam, Pustake, Manas, Kakarala, Chandra , Ammakola, Yagnapriya, Sharma, Anuj, Batra, Nitya, Gandicheruvu, Haritha, Chitkara, Akshit , Mishra, Rahul, Sukaina, Mahnoor , Bagga, Amrita , Pustake, Manas Vaibhav , Ghose, Aruni , Ammakola, Yagnapriya, Ganiyani, Mohammad Arfat , Khosla, Atulya Aman , Garje, Rohan , Singh, Rohit , Jatwani, Karan

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: 58-58

10.1200/jco.2026.44.7_suppl.58 Get It

58 Background: Skeletal-related events (SREs) are a common cause of morbidity and mortality in metastatic castration-resistant prostate cancer (mCRPC). These complications are managed using bone-modifying agents (BMAs), radiation therapy, and surgery, and lead to diminished quality of life irrespective of their castration status. We sought to evaluate the mortality trends for patients with PC and SREs in patients of >65 years from 1999 to 2023 using the CDC WONDER (Wide-ranging Online Data for Epidemiologic Research) database. Methods: The database was searched from January 1, 1999, to December 31, 2023. Mortality trends were assessed by identifying prostate cancer international classification of diseases-10th revision code (ICD-10 code C61) as the underlying cause of death in individuals aged >65 years, and (SREs) as contributing causes using the following ICD-10 codes: S02, S12, S22, S32, S42, S52, S62, S82, S92, T02, T08, T10, T12, T14.2, Y93.2, E55, M80, M81, M84.4. Joinpoint 5.0 software was used to analyze mortality trends. Results: From 1999 to 2023, a total of 3,231 deaths were reported. Trend analysis revealed a decline in overall mortality from 1999 to 2014, with an annual percentage change (APC) of -1.60 (CI: -2.6, -0.5; p = 0.005), followed by a significant increase in mortality from 2015 to 2023, with an APC of 5.30 (p = 0.0001). When stratified by age, individuals aged 65-69 showed an insignificant decline in mortality over the entire study period. For those aged 70-74, mortality significantly decreased from 1999 to 2014 (APC: -3.02, CI: -5.0, -0.9; p = 0.008), but experienced an exponential increase from 2014 to 2023 (APC: 14.07, CI: 8.7, 19.6; p = 0.00005). In the 75-79 age group, mortality significantly decreased from 1999 to 2011 (APC: -5.6, CI: -9.5, -1.6; p = 0.0091), followed by a robust increase from 2011 to 2023 (APC: 7.06, CI: 2.7, 11.5; p = 0.002). For individuals aged >80 years, the trend showed an insignificant decline in mortality from 1999 to 2023 (APC: -0.260, CI: -0.8, 0.3; p = 0.380). Conclusions: Our study revealed significant trends in prostate cancer mortality attributable to SREs, contributing to a sharp increase from 2015 to 2023. Age-stratified analysis revealed that substantial mortality is reported in patients aged 70-79, with the most pronounced rise occurring after 2014. These findings emphasize the growing burden of SREs in older prostate cancer patients, underscoring the need for targeted interventions along with a focus on patient-reported outcomes to improve survival and quality of life.
CAST-AI: Cystectomy after systemic therapy with ADC and immunotherapy.
Zarka, Jabra , Bering, Elisabeth, Flickinger, Lynn M. , Gregory, Susanna, Roberson, Daniel S. , Sharma, Vidit, Chaudhuri, Aadel A. , Khanna, Abhinav, Karnes, R. Jeffrey, Boorjian, S., Sartor, Alton Oliver, Cheville, John C. , Domingo-Doménech, Josep, Shah, Paras H., Orme, Jacob J. , Zarka, Jabra G , Bobek, Olivia , Roberson, Daniel S. , Sharma, Vidit, Pritchett, Joshua C. , Jang, Albert , Karnes, R. Jeffrey , Lucien, Fabrice , Ballman, Karla V. , Domingo‐Domenech, Josep

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: No page available

10.1200/jco.2026.44.7_suppl.tps892 Get It

TPS892 Background: Enfortumab Vedotin (EV) plus pembrolizumab (Pembro) is now first-line therapy for advanced urothelial carcinoma (UC), yielding ~30% complete response (CR) rates; nevertheless, most patients (pts) progress within 1 year and median overall survival (OS) remains < 3 years. In muscle invasive bladder cancer, local consolidation after systemic therapy improves outcomes, suggesting that residual, treatment-refractory intravesical disease drives relapse. We hypothesize that cytoreductive cystectomy/nephroureterectomy (CC/U)—with metastasis-directed therapy (MDT) as needed—can consolidate responses to EV/Pembro and extend benefit in regionally advanced or metastatic UC. CAST-AI prospectively evaluates this multimodal strategy and integrates correlative studies of exosomal Nectin-4 and circulating tumor DNA (ctDNA) from blood and urine as predictive/MRD biomarkers. Methods: CAST-AI is a phase II, decentralized single-arm trial enrolling pts with histologically confirmed UC of the bladder or upper urinary tract with ≥N1 and/or M1 disease and ECOG PS 0–2 who are potential surgical candidates (planned n = 75). Treatment: EV 1.25 mg/kg IV D1 & D8 + Pembro 200 mg IV D1 q21d, ≥4 cycles; MDT permitted any time pre-surgery. Response assessments occur q9 weeks (±4) to 18 months, then q12 weeks (±4). Surgical eligibility requires: (A) fitness for surgery; (B) complete or partial response (CR/PR) or, for select low-burden/unmeasurable disease, urologist-adjudicated candidacy; (C) all distant sites addressed; and (D) procedure in pt’s best interest. Post-CC/U maintenance EV/Pembro is encouraged per clinical discretion and guided by definitive surgical pathology results, which provide true pathologic staging often unattainable through imaging after systemic therapy. Primary endpoint: 12-month progression-free survival (PFS). Secondary endpoints: Objective response rate (ORR), CR rate, down-staging at CC/U, PFS, OS, and safety (using CTCAE). Exploratory endpoints: longitudinal exosomal Nectin-4 and ctDNA dynamics as MRD and early relapse indicators; tissue–blood–urine Nectin-4 concordance; pt-reported tolerability (using CIPN20). Key exclusions: > 20% variant histology or disallowed subtypes (e.g., micropapillary, plasmacytoid, sarcomatoid, neuroendocrine); prior chemotherapy for UC; contraindications to surgery/EV/ICI; or active uncontrolled comorbidities/infections. Status: Enrollment is open and ongoing, with 25 of 75 pts enrolled as of September 2025. The trial uses a decentralized model, allowing pts to receive EV/Pembro at their local facility, with central coordination, biospecimen shipping, and surgical evaluation at Mayo Clinic or affiliated sites. ClinicalTrials.gov: NCT06764095. Clinical trial information: NCT06764095 .
Response of venous tumor thrombi in renal cell carcinoma to immune checkpoint inhibitor therapy: A multicenter retrospective cohort study.
Li, Eric, Wang, Michael, Dorr, Maddy, Roberson, Daniel S. , McLeay, Matthew T. , Basourakos, Spyros, Khanna, Abhinav, Costello, Brian A. , Boorjian, S., Leibovich, Bradley C. , Sharma, Vidit, Li, Eric, Roberson, Daniel S. , Lyon, Timothy D. , Zakharia, Yousef , Sharma, Vidit

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: 496-496

10.1200/jco.2026.44.7_suppl.496 Get It

496 Background: Approximately 10% of patients with renal cell carcinoma (RCC) have an associated venous tumor thrombus (VTT), the presence of which impacts surgical management and increases perioperative risk. Historical systemic therapy regimens had limited success in downsizing VTT; however, the impact of immune checkpoint inhibitors (ICIs) on VTT shrinkage is unknown. Our primary objective is to assess VTT shrinkage comparing responses to ICI versus non-ICI regimens. Methods: This multicenter retrospective cohort study included patients with RCC and VTT from 2006-2024 who received upfront systemic therapy. Patients were evaluated at tertiary referral centers across Mayo Clinic Rochester, Florida, and Arizona. Systemic therapies were categorized as ICI versus non-ICI regimens. VTT length was quantified by distance relative to the superior border of the renal vein ostium. The primary outcome was change in VTT length on serial imaging as measured by absolute length reduction (cm), RECIST version 1.1 criteria, and Mayo VTT level reclassification. Linear mixed-effect models (LMMs) identified associations with VTT shrinkage and clinicopathologic features. Results: A total of 108 patients with median age 65 years (IQR 57-71) were included, of whom 49 (45%) received ICI regimens. ICI regimens were associated with greater VTT shrinkage (1cm vs 0.1 cm, p=0.025), increased RECIST responses (51% vs 32%, p=0.046), and a higher rate downstaging per Mayo VTT level (33% vs 12%, p=0.008) compared to non-ICI regimens. On multivariable LMM analysis, ICI regimens remained more likely to result in VTT shrinkage compared to non-ICI regimens (-0.12 cm/month, 95% CI –0.24-0.00, p=0.046). Absence of abdominal lymphadenopathy was also associated with VTT shrinkage (-0.18cm/month, 95% CI -0.06- -0.30, p=0.004). Initial Mayo VTT level, IMDC risk, and number of metastatic sites were not associated with VTT shrinkage. Conclusions: Treatment with ICI-regimens resulted in VTT shrinkage and Mayo VTT level reduction. This is a particularly important area of exploration as radical nephrectomy and tumor thrombectomy carry up to a 40% risk of peri-operative major complications. These data support using ICI regimens for patients with RCC with VTT who are not candidates for upfront surgery and prioritizing ICI regimens in neoadjuvant clinical trials.
Recurrent Stroke in Patients With Cryptogenic Stroke and Left Ventricular Injury: The Cardiac Abnormalities in Stroke Prevention and Recurrence (CASPR) Study
Sharma, Richa, McNamara, Katelyn F. , Goicoechea, Elena Badillo, Bowman, Anna , Coevering, Russell J. Van , Chen, Lucia , Penckofer, Mary, Singh, Eesha , Kerrigan, Deborah, Nahab, Fadi, Glover, Patrick , Krishnaiah, Balaji , Yaghi, Shadi, Khasiyev, Farid, Lineback, Christina, Melkumova, Emiliya , Nguyen, Thanh N., Thompson, Sean, Daniel, Jean-Philippe Auguste, Aziz, Yasmin, Alvi, Muhammad , Herpich, Franziska , Shahrivari, Mahan, Chionatos, Rafail , Elangovan, Cheran, Kang, Jieun, Zha, Alicia , Farooqui, Mudassir, Rothstein, Aaron, Khan, Farhan, Smith, Matthew , Brown, Samantha, Qdais, Ahmad Abu, Liebeskind, David S., Abburi, Nandini , Rozental, Stefano, Nedelcu, Simona , Thon, Jesse M., Stretz, Christoph, Thottempudi, Neeharika, Yu, Wenzheng, Eklund, Kelsey , Linares, Guillermo, Havenon, Adam de, Siegler, James E., Liebeskind, David S. , Sharma, Richa , Brown, Samantha , Lineback, Christina , Penckofer, Mary , Kerrigan, Deborah , Badillo‐Goicoechea, Elena , Sharma, Richa , Goicoechea, Elena Badillo , Van Coevering, Russell J , Penckofer, Mary , Kerrigan, Deborah , Aboul-Nour, Hassan , Nahab, Fadi B , Krishnaiah, Balaji , Yaghi, Shadi , Khasiyev, Farid , Lineback, Christina M , Melkumova, Emiliya , Culbertson, Collin J , Nguyen, Thanh N , Jillella, Dinesh V , Aziz, Yasmin , Herpich, Franziska , Chionatos, Rafail A , Elangovan, Cheran , Zha, Alicia , Farooqui, Mudassir , Rothstein, Aaron , Khan, Farhan , Smith, Matthew M , Brown, Samantha J , Abu Qdais, Ahmad , Liebeskind, David S. , Abburi, Nandini , Nedelcu, Simona , Thon, Jesse , Stretz, Christoph , Eklund, Kelsey , Linares, Guillermo , de Havenon, Adam H , Siegler, James E , Daniel, Jean-Philippe Auguste , Nour, Hassan Aboul , Yaghi, Shadi , Nguyen, Thanh N. , Jillella, Dinesh , Aziz, Yasmin , Elangovan, Cheran , Rothstein, Aaron , Khan, Farhan , Rozental, Stefano Freitas Andrade, Thon, Jesse , Stretz, Christoph , Thottempudi, Neeharika , Yu, Wenzheng, Linares, Guillermo , Havenon, Adam de , Siegler, James E.

Mayo Clinic

Stroke | March 2, 2026 | Volume: 57 | Issue: 5 | Pages: 1175-1186

10.1161/strokeaha.125.053755 | PMID 41766531 Get It

BACKGROUND: Left ventricular (LV) dysfunction is a potential cardioembolic source of ischemic stroke, but its role in recurrent stroke risk and treatment response remains unclear. We explore whether LV injury associates with the risk of recurrent stroke and modifies the association between anticoagulation and stroke recurrence using real-world data. METHODS: We performed a multicenter, retrospective study of Cardiac Abnormalities in Stroke Prevention and Recurrence cohort across 27 US sites. Patients with LV ejection fraction ≥20% were included. LV injury, defined as LV ejection fraction 20% to 40% and wall motion abnormality, was the primary exposure and treatment effect modifier. The treatment of interest was anticoagulant versus antiplatelet therapy. The composite outcome included recurrent stroke, major bleeding, or death. Outcomes were evaluated using unadjusted and inverse probability weighting adjusted Cox proportional hazards models, with treatment effect modification tested by LV injury status. RESULTS: Among 2685 patients enrolled, 2328 with complete data were analyzed (median age, 65 years; 49.8% female; median follow-up, 1.6 years). LV injury was present in 310 patients (13.3%). Overall, 535 events occurred: 258 recurrent ischemic strokes, 28 hemorrhagic strokes, 67 major hemorrhages, and 256 deaths. LV injury was associated with a higher unadjusted risk of the primary outcome (hazard ratio [HR], 1.51 [95% CI, 1.21–1.87]), though nonsignificant after inverse probability weighting adjustment (adjusted HR, 1.29 [95% CI, 0.97–1.70]). In the LV injury subgroup, anticoagulation versus antiplatelet therapy was associated with a lower risk of the primary outcome (adjusted HR, 0.24 [95% CI, 0.10–0.59]), relative to the non-LV injury subgroup (adjusted HR, 1.28 [95% CI, 0.83–1.95]; p[LV-interaction], 0.001). Similar interactions were seen for EF 20% to 40% (versus >40%; adjusted HR, 0.19 [95% CI, 0.04–0.86]; p[LV-interaction], 0.001) and wall motion abnormality (versus no wall motion abnormality; adjusted HR, 0.33 [95% CI, 0.15–0.73]). CONCLUSIONS: After cryptogenic stroke, anticoagulation in those with LV injury was associated with lower rates of recurrent stroke, major bleeding, and death. These findings warrant confirmation in a dedicated randomized controlled trial. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06398366.